SCHEMBL1127590

SCHEMBL1127590

O=C(O)C(Cc1ccc(Cl)cc1)c1ccccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.46
BLM P54132 1/20 0.45
LMNA P02545 1/20 0.45
PMP22 Q01453 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
PPARG P37231 7/20 0.44
PPARA Q07869 7/20 0.44
CHRM2 P08172 2/20 0.44
CHRM5 P08912 2/20 0.44
CHRM1 P11229 2/20 0.44
ADRA2B P18089 2/20 0.44
SLC6A2 P23975 2/20 0.44
HRH2 P25021 2/20 0.44
HTR2A P28223 2/20 0.44
SLC6A4 P31645 2/20 0.44
HRH1 P35367 2/20 0.44
SLC6A3 Q01959 2/20 0.44
KCNH2 Q12809 2/20 0.44
HRH3 Q9Y5N1 2/20 0.44
CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1127361 0.89 CYP1A2 (0.53) NPSR1CYP2D6TSHRP4HTMCYP1A2
SCHEMBL3373228 0.87 KMT2A (0.45) KMT2ABLMLMNAPMP22NPSR1
SCHEMBL1127707 0.82 KMT2A (0.52) KMT2ABLMLMNAPMP22NPSR1
SCHEMBL1127294 0.82 MME (0.41) NPSR1PPARGP4HTMMMECYP1A2
SCHEMBL1127419 0.81 KDM4E (0.42) KMT2ASLC6A2P4HTMCYP1A2
SCHEMBL1127390 0.79 KMT2A (0.48) KMT2ABLMLMNAPMP22NPSR1
SCHEMBL1127686 0.78 PTPRA (0.41) NPSR1PPARGPPARASLC6A2SLC6A4
SCHEMBL3370947 0.78 EPHX1 (0.56) PPARGPPARACYP2C9P4HTMPOLB
SCHEMBL2583959 0.78 CYP1A2 (0.47) KMT2ALMNANPSR1SLC6A2SLC6A4
SCHEMBL1127394 0.78 MME (0.39) KMT2ABLMLMNAPMP22NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2283002-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION Intermune, Inc. (US) 2011-02-16 EP disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF KMT2A 2735/4885BLM 724/4885LMNA 2638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.